Paclitaxel-Conditioned Mesenchymal Stem Cells Enhance T Cell Activation and Cytotoxicity Against CD44+/CD24− Breast Cancer Stem Cells

Authors

  • Dedy Hermansyah Department of Surgery, Faculty of Medicine, Universitas Sumatera Utara, North Sumatera, Medan, Indonesia
  • Siti Syarifah 2Department of Pharmacology, Faculty of Medicine, Universitas Sumatera Utara, North Sumatera, Medan, Indonesia
  • Adi Muradi Muhar Department of Doctoral Degree Program, Faculty of Medicine, Universitas Sumatera Utara, North Sumatera, Medan, Indonesia
  • Nur Dina Amalina Pharmaceutical Sciences Department, Faculty of Medicine, Universitas Negeri Semarang, Semarang, Indonesia

DOI:

https://doi.org/10.48048/tis.2027.14177

Keywords:

Breast cancer stem cells, Mesenchymal stem cells, Paclitaxel, T cell activation, Immunotherapy, CD44⁺/CD24⁻

Abstract

Breast cancer stem cells (BCSCs) represent a critical population responsible for tumor recurrence, metastasis, and therapeutic resistance. Despite advances in immunotherapy, targeting BCSCs remains challenging due to their immune evasion mechanisms and limited T cell infiltration. To investigate the potential of paclitaxel-conditioned mesenchymal stem cells (MSCs) in enhancing T cell activation and cytotoxicity against CD44⁺/CD24⁻ breast cancer stem cells. BCSCs were isolated from MDA-MB-231 cells using magnetic-activated cell sorting (MACS) and characterized by flow cytometry. MSCs derived from umbilical cord blood were treated with paclitaxel (10 - 20 μg/mL) for 72 h to generate conditioned medium (CM-MSCs-Pax). CD8+ T cells were isolated from tumor-bearing BALB/c mice and activated using CM-MSCs-Pax. T cell activation was assessed by IL2RA (CD25) expression via qRT-PCR. Co-culture experiments evaluated cytotoxicity against BCSCs using the MTT assay, and molecular mechanisms were examined by analyzing caspase-3 and PD-L1 expression. MACS sorting successfully enriched CD44⁺/CD24⁻ BCSCs to 80.7% purity. Paclitaxel treatment significantly enhanced MSC secretion of IL-6, TNF-α, and IL-10 in conditioned medium. CM-MSCs-Pax treatment increased T cell activation, demonstrated by elevated IL2RA expression. Co-culture of activated T cells with BCSCs at a 10:1 ratio reduced BCSC viability to 9.68% at 72 h compared to 30.20% with unactivated T cells. This enhanced cytotoxicity was associated with increased caspase-3 expression and reduced PD-L1 expression in BCSCs. Paclitaxel-conditioned MSCs create a pro-inflammatory microenvironment that enhances T cell activation and cytotoxicity against BCSCs. This novel approach combining chemotherapy conditioning with immunotherapy represents a promising strategy for targeting therapy-resistant breast cancer stem cell populations.

HIGHLIGHTS

  • Paclitaxel-conditioned MSCs (CM-MSCs-Pax) enhance CD8+ T cell activation against breast cancer stem cells (BCSCs).
  • CM-MSCs-Pax increases pro-inflammatory cytokine secretion (IL-6, TNF-α, IL-10).
  • Activated T cells exhibit significantly enhanced cytotoxicity against CD44+/CD24−
  • BCSC viability decreases to ~9.7% at 72 h with CM-MSCs-Pax–activated T cells.
  • Enhanced killing is associated with increased caspase-3 and reduced PD-L1 expression.
  • Chemotherapy-conditioned MSCs offer a promising strategy to overcome BCSC immune resistance.

GRAPHICAL ABSTRACT

Downloads

Download data is not yet available.

References

SM Lima, RD Kehm and MB Terry. Global breast cancer incidence and mortality trends by region, age-groups, and fertility patterns. eClinicalMedicine 2021; 38, 100985.

H Zeng and G Lu. Research progress of breast cancer stem cell stemness and breast cancer recurrence. Journal of Biosciences and Medicines 2024; 12(8), 281-294.

Y Feng, M Spezia, S Huang, C Yuan, Z Zeng, L Zhang, X Ji, W Liu, B Huang, W Luo, B Liu, Y Lei, S Du, A Vuppalapati, HH Luu, RC Haydon, TC He and G Ren. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes & Diseases 2018; 5(2), 77-106.

W Shuo, Z Ying, C Weihong, L Jie, Z Yuren, F Huiting, X Yonggang, L Hongsheng and HS Lin. Breast cancer stem-like cells can promote metastasis by activating platelets and down-regulating antitumor activity of natural killer cells. Journal of Traditional Chinese Medicine 2016; 36(4), 530-537.

JS Crabtree and L Miele. Breast cancer stem cells. Biomedicines 2018; 6(3), 77.

D Hermansyah, S Syarifah, AM Muhar and A Putra. Unveiling paclitaxel-induced mesenchymal stem cells: Orchestrating Nrf2 modulation and apoptosis in CD44⁺/CD24⁻ cancer stem cells. Breast Cancer: Targets and Therapy 2024; 16, 319-328.

MA Elbaiomy, T Akl, N Atwan, AA Elsayed, M Elzaafarany and S Shamaa. Clinical impact of breast cancer stem cells in metastatic breast cancer patients. Journal of Oncology 2020; 2020, 2561726.

WC Sin and CL Lim. Breast cancer stem cells—from origins to targeted therapy. Stem Cell Investigation 2017; 4, 96.

LV Nalla, K Kalia and A Khairnar. Self-renewal signaling pathways in breast cancer stem cells. The International Journal of Biochemistry & Cell Biology 2019; 107, 140-153.

P Darvin, VS Nair and E Elkord. PD-L1 expression in human breast cancer stem cells is epigenetically regulated through posttranslational histone modifications. Journal of Oncology 2019; 2019, 3958908.

S Almozyan, D Colak, F Mansour, A Alaiya, O Al-Harazi, A Qattan, F Al-Mohanna, M Al-Alwan and H Ghebeh. PD-L1 promotes OCT4 and Nanog expression in breast cancer stem cells by sustaining PI3K/AKT pathway activation. International Journal of Cancer 2017; 141(7), 1402-1412.

J Chu, Y Li, X Fan, J Ma, J Li, G Lu, Y Zhang, Y Huang, W Li, X Huang, Z Fu, Y Yin and H Yuan. MiR-4319 suppress the malignancy of triple-negative breast cancer by regulating self-renewal and tumorigenesis of stem cells. Cellular Physiology and Biochemistry 2018; 48(2), 593-604.

T Li, C Zhang, Y Ding, W Zhai, K Liu, F Bu, T Tu, L Sun, W Zhu, F Zhou, W Qi, J Hu, H Chen and X Sun. Umbilical cord-derived mesenchymal stem cells promote proliferation and migration in MCF-7 and MDA-MB-231 breast cancer cells through activation of the ERK pathway. Oncology Reports 2015; 34(3), 1469-1477.

M Szewc, E Radzikowska-Bűchner, P Wdowiak, J Kozak, P Kuszta, E Niezabitowska, J Matysiak, K Kubiński and M Masłyk. MSCs as tumor-specific vectors for the delivery of anticancer agents—a potential therapeutic strategy in cancer diseases: Perspectives for quinazoline derivatives. International Journal of Molecular Sciences 2022; 23(5), 2745.

R Hass. Role of msc in the tumor microenvironment. Cancers 2020; 12(8), 2107.

HM Nawara, SM Afify, G Hassan, MH Zahra, A Seno and M Seno. Paclitaxel-based chemotherapy targeting cancer stem cells from mono- to combination therapy. Biomedicines 2021; 9(5), 500.

RC Sterner and RM Sterner. CAR-T cell therapy: Current limitations and potential strategies. Blood Cancer Journal 2021; 11(4), 69.

C D’Accardo, G Porcelli, LR Mangiapane, C Modica, VD Pantina, N Roozafzay, S Di Franco, M Gaggianesi, V Veschi, M Lo Iacono, M Todaro, A Turdo and G Stassi. Cancer cell targeting by CAR-T cells: A matter of stemness. Frontiers in Molecular Medicine 2022; 2, 1055028.

HE Marei, K Bedair, A Hasan, L Al-Mansoori, S Caratelli, G Sconocchia, A Gaiba and C Cenciarelli. Current status and innovative developments of CAR-T-cell therapy for the treatment of breast cancer. Cancer Cell International 2025; 25(1), 3.

H Wang, G Kaur, AI Sankin, F Chen, F Guan and X Zang. Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies. Journal of Hematology & Oncology 2019; 12(1), 59.

M Suzery, B Cahyono and ND Amalina. Citrus sinensis (L) peels extract inhibits metastasis of breast cancer cells by targeting the downregulation matrix metalloproteinases-9. Open Access Macedonian Journal of Medical Sciences 2021; 9(B), 464-469.

M Suzery, B Cahyono and ND Amalina. Antiproliferative and apoptosis effect of hyptolide from Hyptis pectinata (L.) Poit on human breast cancer cells. Journal of Applied Pharmaceutical Science 2020; 10(2), 001-006.

M Fredianto, H Herman, YD Ismiarto, A Putra, I Alif, ND Amalina and MA Nazar. Secretome of hypoxia-preconditioned mesenchymal stem cells enhance the expression of HIF-1a and bFGF in a rotator cuff tear model. Medicinski Glasnik 2023; 20(2), 242-248.

AM Muhar, F Makharim, D Hermansyah, A Putra, N Hidayah, ND Amalina and I Alif. Hypoxic mesenchymal stem cell-conditioned medium accelerates wound healing by regulating IL-10 and TGF-β levels in a full-thickness-wound rat model. Indonesian Journal of Biotechnology 2022; 27(4), 187-194.

YW Prajoko, A Putra, BT Dirja, AM Muhar and ND Amalina. The ameliorating effects of MSCs in controlling Treg-mediated B-cell depletion by indoleamine 2, 3-dioxygenase induction in PBMC of SLE patients. Open Access Macedonian Journal of Medical Sciences 2022; 10(A), 6-11.

BT Dirja, EH Wardoyo, A Putra and ND Amalina. Enhanced third degree burn wound healing by hypoxic mesenchymal stem cells’ secretome: IL-10 upregulation and TNF-α/PGE2 suppression. Trends in Sciences 2024; 21(10), 8288.

A Chaudhry, RM Samstein, P Treuting, Y Liang, MC Pils, JM Heinrich, RS Jack, FT Wunderlich, JC Brüning, W Müller and AY Rudensky. Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. Immunity 2011; 34(4), 566-578.

DA Paramita, D Hermansyah and ND Amalina. Regulation of p53 and survivin by Curcuma longa extract to caspase-3 dependent apoptosis in triple negative breast cancer cells. Medicinski Glasnik 2022; 19(2), 189-196.

Q Tang, Y Chen, X Li, S Long, Y Shi, Y Yu, W Wu, L Han and S Wang. The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Frontiers in Immunology 2022; 13, 964442.

MG Scioli, G Storti, F D’Amico, P Gentile, G Fabbri, V Cervelli and A Orlandi. The role of breast cancer stem cells as a prognostic marker and a target to improve the efficacy of breast cancer therapy. Cancers 2019; 11(7), 1021.

H Xu, Y Zhou, W Li, B Zhang, H Zhang, S Zhao, P Zheng, H Wu and J Yang. Tumor-derived mesenchymal-stem-cell-secreted IL-6 enhances resistance to cisplatin via the STAT3 pathway in breast cancer. Oncology Letters 2018; 15(6), 9142-9150.

DE Johnson, RA O'Keefe and JR Grandis. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nature Reviews Clinical Oncology 2018; 15(4), 234-248.

T Hirano. IL-6 in inflammation, autoimmunity and cancer. International Immunology 2021; 33(3), 127-148.

H Jeong, J Koh, S Kim, J Yim, SG Song, H Kim, Y Li, SH Lee, YK Chung, H Kim, CH Lee, HY Kim, B Keam, SH Lee, DH Chung and YK Jeon. Cell-intrinsic PD-L1 signaling drives immunosuppression by myeloid-derived suppressor cells through IL-6/Jak/Stat3 in PD-L1-high lung cancer. Journal for ImmunoTherapy of Cancer 2025; 13(3), e010612.

SA Nish, D Schenten, T Wunderlich, SD Pope, Y Gao, N Hoshi, S Yu, X Yan, HK Lee, L Pasman, I Brodsky, B Yordy, H Zhao, J Bruning and R Medzhitov. T cell-intrinsic role of IL-6 signaling in primary and memory responses. eLife 2014; 3, e01949.

B Huang, X Lang and X Li. The role of IL-6/JAK2/STAT3 signaling pathway in cancers. Frontiers in Oncology 2022; 12, 1023177.

Y Wang, AHH Van Boxel-Dezaire, H Cheon, J Yang and GR Stark. STAT3 activation in response to IL-6 is prolonged by the binding of IL-6 receptor to EGF receptor. Proceedings of the National Academy of Sciences of the United States of America 2013; 110(42), 16975-16980.

FK Hartati, SB Widjanarko, TD Widyaningsih and M Rifa’i. Anti-inflammatory evaluation of black rice extract inhibits TNF-α, IFN-γ and IL-6 cytokines produced by immunocompetent cells. Food and Agricultural Immunology 2017; 28(6), 1116-1125.

A Putra, FB Ridwan, AI Putridewi, AR Kustiyah, K Wirastuti, NAC Sadyah, I Rosdiana and D Munir. The role of TNF-α induced MSCs on suppressive inflammation by increasing TGF-β and IL-10. Open Access Macedonian Journal of Medical Sciences 2018; 6(10), 1779-1783.

DM Darlan, D Munir, A Putra, I Alif, ND Amalina, NK Jusuf and IB Putra. Revealing the decrease of indoleamine 2,3-dioxygenase as a major constituent for B cells survival post-mesenchymal stem cells co-cultured with peripheral blood mononuclear cell (PBMC) of systemic lupus erythematosus (SLE) patients. Medicinski Glasnik 2022; 19(1), 12-18.

J Xi, M Xu, Z Song, H Li, S Xu, C Wang, H Song and J Bai. Stimulatory role of interleukin 10 in CD8+ T cells through STATs in gastric cancer. Tumor Biology 2017; 39(5), 1010428317706209.

Z Guo, Q He, Y Zhang, Y Li and Z Zhang. Mechanisms of interleukin-10-mediated immunosuppression in viral infections. Pathogens 2025; 14(10), 989.

G Wang, D Zhang, S Yang, Y Wang, Z Tang and X Fu. Co-administration of genistein with doxorubicin-loaded polypeptide nanoparticles weakens the metastasis of malignant prostate cancer by amplifying oxidative damage. Biomaterials Science 2018; 6(4), 827-835.

ND Amalina, IP Nurhayati and E Meiyanto. Doxorubicin induces lamellipodia formation and cell migration. Indonesian Journal of Cancer Chemoprevention 2017; 8(2), 61-67.

S Ran. The role of TLR4 in chemotherapy-driven metastasis. Cancer Research 2015; 75(12), 2405-2410.

J Abdi, I Rashedi and A Keating. Concise review: TLR pathway-miRNA interplay in mesenchymal stromal cells: Regulatory roles and therapeutic directions. Stem Cells 2018; 36(11), 1655-1662.

LW Pfannenstiel, SS Lam, LA Emens, EM Jaffee and TD Armstrong. Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice. Cellular Immunology 2010; 263(1), 79-87.

MA Huseni, L Wang, JE Klementowicz, K Yuen, B Breart, C Orr, LF Liu, Y Li, V Gupta, C Li, D Rishipathak, J Peng, Y Şenbabaoǧlu, Z Modrusan, S Keerthivasan, S Madireddi, YJ Chen, EJ Fraser, N Leng, H Hamidi, H Koeppen, J Ziai, K Hashimoto, M Fassò, P Williams, DF McDermott, JE Rosenberg, T Powles, LA Emens, PS Hegde, I Mellman, SJ Turley, MS Wilson, S Mariathasan, L Molinero, M Merchant and NR West. CD8+ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy. Cell Reports Medicine 2023; 4(1), 100878.

X Pu, SJ Storr, Y Zhang, EA Rakha, AR Green, IO Ellis and SG Martin. Caspase-3 and caspase-8 expression in breast cancer: Caspase-3 is associated with survival. Apoptosis 2017; 22(3), 357-368.

KM Zak, P Grudnik, K Magiera, A Dömling, G Dubin and TA Holak. Structural biology of the immune checkpoint receptor PD-1 and its ligands PD-L1/PD-L2. Structure 2017; 25(8), 1163-1174.

M Elfoly, JY Mirza, A Alaiya, AA Al-Hazzani, A Tulbah, M Al-Alwan and H Ghebeh. PD-L1 intrinsically promotes the proliferation of breast cancer cells through the SKP2-p27/p21 axis. Cancer Cell International 2024; 24(1), 161.

M Jin, J Fang, J Peng, X Wang, P Xing, K Jia, J Hu, D Wang, Y Ding, X Wang, W Li and Z Chen. PD-1/PD-L1 immune checkpoint blockade in breast cancer: Research insights and sensitization strategies. Molecular Cancer 2024; 23(1), 266.

Downloads

Published

2026-08-25

How to Cite

Hermansyah, D., Syarifah, S., Muhar, A. M., & Amalina, N. D. (2026). Paclitaxel-Conditioned Mesenchymal Stem Cells Enhance T Cell Activation and Cytotoxicity Against CD44+/CD24− Breast Cancer Stem Cells. Trends in Sciences, 24(1), 14177. https://doi.org/10.48048/tis.2027.14177

Most read articles by the same author(s)